Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OCU 410 ST

Next Previous
X
Search
Drug Profile

OCU 410 ST

Alternative Names: AAV5-hRORA; OCU-410-ST

Latest Information Update: 03 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Schepens Eye Research Institute
  • Developer Ocugen
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene transference; Nuclear receptor subfamily 1 group F member 1 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stargardt disease; Retinitis pigmentosa; Cone rod dystrophies
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Stargardt disease
  • Preclinical Cone rod dystrophies; Retinitis pigmentosa

Most Recent Events

  • 01 Apr 2024 Adverse event data from the phase I/II GARDian trial in Stargardt disease released by Ocugen
  • 25 Aug 2023 Phase-I/II clinical trials in Stargardt disease (In children, In adults) in USA (Subretinal) (NCT05956626)
  • 21 Aug 2023 Ocugen plans phase-I/II trial for Stargardt disease by the end of 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top